Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata.


Journal

American journal of clinical dermatology
ISSN: 1179-1888
Titre abrégé: Am J Clin Dermatol
Pays: New Zealand
ID NLM: 100895290

Informations de publication

Date de publication:
Oct 2020
Historique:
pubmed: 18 8 2020
medline: 25 5 2021
entrez: 18 8 2020
Statut: ppublish

Résumé

Eyebrow and eyelash hair loss and nail damage-in addition to scalp hair loss-are important signs/symptoms of alopecia areata (AA) to patients and deserve assessment in AA clinical trials. Our objective was to develop clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures and accompanying photoguides to aid in the assessment of AA-related eyebrow, eyelash and nail signs/symptoms. Iterative rounds of qualitative, semi-structured interviews were conducted with US expert dermatologists and North American patients with AA. Patients with eyebrow, eyelash and nail involvement were purposefully sampled. Interview transcripts were qualitatively analyzed. Dermatologists (n = 10) described eyebrow and eyelash loss as concerning for affected patients and, along with nail appearance, as deserving assessment. Dermatologist data informed the development of single item, 4-point Likert-type ClinRO and PRO measures of current eyebrow loss, eyelash loss and nail appearance and a PRO measure of eye irritation. Patients (n = 45, age 15-72 years) confirmed the importance and relevance of these signs/symptoms. Interim revision resulted in measures that were understood by and relevant to patients. Dermatologists (n = 5) and patients (n = 10, age 21-54 years) participated in the development of the eyebrow, eyelash and nail photoguides and confirmed that they included photos that appropriately represented different severity levels and were helpful to derive and standardize ratings across raters. The ClinRO and PRO measures for eyebrow, eyelash and nail appearance, with their accompanying photoguides and the PRO Measure for Eye Irritation provide clear and meaningful assessments of outcomes important to patients with AA.

Sections du résumé

BACKGROUND BACKGROUND
Eyebrow and eyelash hair loss and nail damage-in addition to scalp hair loss-are important signs/symptoms of alopecia areata (AA) to patients and deserve assessment in AA clinical trials.
OBJECTIVES OBJECTIVE
Our objective was to develop clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures and accompanying photoguides to aid in the assessment of AA-related eyebrow, eyelash and nail signs/symptoms.
METHODS METHODS
Iterative rounds of qualitative, semi-structured interviews were conducted with US expert dermatologists and North American patients with AA. Patients with eyebrow, eyelash and nail involvement were purposefully sampled. Interview transcripts were qualitatively analyzed.
RESULTS RESULTS
Dermatologists (n = 10) described eyebrow and eyelash loss as concerning for affected patients and, along with nail appearance, as deserving assessment. Dermatologist data informed the development of single item, 4-point Likert-type ClinRO and PRO measures of current eyebrow loss, eyelash loss and nail appearance and a PRO measure of eye irritation. Patients (n = 45, age 15-72 years) confirmed the importance and relevance of these signs/symptoms. Interim revision resulted in measures that were understood by and relevant to patients. Dermatologists (n = 5) and patients (n = 10, age 21-54 years) participated in the development of the eyebrow, eyelash and nail photoguides and confirmed that they included photos that appropriately represented different severity levels and were helpful to derive and standardize ratings across raters.
CONCLUSIONS CONCLUSIONS
The ClinRO and PRO measures for eyebrow, eyelash and nail appearance, with their accompanying photoguides and the PRO Measure for Eye Irritation provide clear and meaningful assessments of outcomes important to patients with AA.

Identifiants

pubmed: 32803546
doi: 10.1007/s40257-020-00545-9
pii: 10.1007/s40257-020-00545-9
pmc: PMC7473969
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

725-732

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States

Références

Value Health. 2018 Jul;21(7):839-842
pubmed: 30005756
Br Med J. 1950 Dec 2;2(4691):1250-2
pubmed: 14791998
Dermatol Ther. 2011 May-Jun;24(3):348-54
pubmed: 21689244
BMJ. 2005 Oct 22;331(7522):951-3
pubmed: 16239692
J Investig Dermatol Symp Proc. 2013 Dec;16(1):S73-6
pubmed: 24326568
Value Health. 2011 Dec;14(8):978-88
pubmed: 22152166
Dermatol Surg. 2016 May;42(5):608-17
pubmed: 27124878
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
Int J Dermatol. 2018 Jul;57(7):776-783
pubmed: 29318582
Perception. 2003;32(3):285-93
pubmed: 12729380
J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):242-6
pubmed: 10025752
J Investig Dermatol Symp Proc. 2015 Nov;17(2):63-6
pubmed: 26551952
Br J Dermatol. 2020 Dec;183(6):1065-1072
pubmed: 32163589
J Am Acad Dermatol. 2004 Sep;51(3):440-7
pubmed: 15337988
Br J Dermatol. 2020 Oct;183(4):702-709
pubmed: 31970750

Auteurs

Kathleen W Wyrwich (KW)

Patient-Focused Outcomes Center of Expertise, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.

Helen Kitchen (H)

Clinical Outcomes Assessment, DRG Abacus, The Lexicon, Mount Street, Manchester, M2 5NT, UK.

Sarah Knight (S)

Clinical Outcomes Assessment, DRG Abacus, The Lexicon, Mount Street, Manchester, M2 5NT, UK.

Natalie V J Aldhouse (NVJ)

Clinical Outcomes Assessment, DRG Abacus, The Lexicon, Mount Street, Manchester, M2 5NT, UK.

Jake Macey (J)

Clinical Outcomes Assessment, DRG Abacus, The Lexicon, Mount Street, Manchester, M2 5NT, UK.

Fabio P Nunes (FP)

Lilly Bio-Medicines, Eli Lilly and Company, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.

Yves Dutronc (Y)

Lilly Bio-Medicines, Eli Lilly and Company, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.

Natasha Mesinkovska (N)

University of California Irvine Dermatology Clinical Research Center, Hewitt Hall Building, 843 Health Sciences Road, Room 1001, Irvine, CA, 92697, USA.

Justin M Ko (JM)

Stanford Dermatology, Stanford University School of Medicine, 291 Campus Drive, Li Ka Shing Building, Stanford, CA, 94305-5101, USA.

Brett A King (BA)

Department of Dermatology, Yale School of Medicine, 333 Cedar Street, LMP 5040, New Haven, CT, 06520, USA. brett.king@yale.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH